NORMAL SITUATION

FLANDERSBIO

Financial year 2024 · closed on 31/12/2024
Net result
-355,7 k €
-2805.0% YoY
Revenue
898 k €
-16.0% YoY
Equity
825,7 k €
-30.1% YoY
Workforce
5,6 ETP
-16.4% YoY

Company — Normal situation.

What does FLANDERSBIO do?

FLANDERSBIO is a company registered in Belgium. It employs on average 5,6 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0863.763.620
Legal form
Non-profit organization
Latest accounts
31/12/2024
Average workforce
5,6 ETP
Joint committees (2)
  • 200
  • 335
Signals
Solid equityGood liquidityHealthy social debts
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 17 financial years

20242023202220212020201920182017201620152014201320122011201020092008
Income statement
Revenue898 k €1,1 M €274,2 k €178,4 k €
EBITDA-327,4 k €31,2 k €-83,2 k €353,9 k €344,3 k €324,4 k €60,8 k €-116,9 k €-12,6 k €-1,9 k €57,3 k €187,3 k €53,4 k €84,8 k €123,7 k €-6,3 k €-20,4 k €
Operating result-369,2 k €9,7 k €-106,4 k €330,8 k €329,6 k €299,7 k €19 k €-145,5 k €-42,1 k €-15,7 k €29,2 k €140,5 k €22,8 k €50,9 k €93 k €-21,5 k €-28,9 k €
Net result-355,7 k €13,1 k €-108,9 k €323,5 k €322,1 k €261,4 k €14,5 k €-145,2 k €-26,6 k €-38,5 k €24,8 k €137,4 k €8,3 k €26,2 k €85,8 k €-22,3 k €-26,5 k €
Balance sheet
Equity825,7 k €1,2 M €1,2 M €1,3 M €953,6 k €631,6 k €370,2 k €355,7 k €500,9 k €527,6 k €566,1 k €541,3 k €403,9 k €395,6 k €369,4 k €283,6 k €305,9 k €
Total assets1,2 M €1,7 M €1,5 M €1,5 M €1,1 M €1,1 M €829,8 k €1,4 M €886,4 k €914,1 k €882,8 k €662 k €597,6 k €626,7 k €673,7 k €458,9 k €472,2 k €
Cash46,5 k €158,2 k €934,1 k €969,9 k €537,3 k €579,3 k €198,9 k €177,5 k €264,5 k €246,2 k €247 k €269,7 k €139,5 k €216,4 k €245,7 k €177,9 k €96 k €
Debts176,4 k €159,4 k €147,7 k €125,2 k €96,4 k €155,3 k €110,1 k €317,8 k €147,5 k €147,3 k €159,9 k €80,8 k €115,5 k €127,2 k €195,6 k €109,2 k €71,3 k €
Other
Workforce5,6 ETP6,7 ETP6,9 ETP5,7 ETP5,7 ETP5,0 ETP4,8 ETP6,9 ETP7,4 ETP6,8 ETP6,1 ETP5,6 ETP5,6 ETP6,5 ETP6,2 ETP6,7 ETP5,6 ETP
Governance

Board of directors

Seen on filing of 31/12/2024 · 18 active · 159 ended

Active mandates

2 BRIDGE

Director · since 20 juin 2024 · until 20 juin 2028 · 0540.765.892

Represented by Ann Meulemans

Active
Participatiemaatschappij Vlaanderen

Director · since 20 juin 2024 · until 20 juin 2028 · 0455.777.660

Represented by Kenneth Wils

Active
QbD Group

Director · since 20 juin 2024 · until 20 juin 2028 · 0838.540.254

Represented by Bart Van Acker

Active
Aphea.Bio

Director · since 27 avril 2023 · until 27 avril 2027 · 0666.961.607

Represented by Isabel Vercauteren

Active
Newton Biocapital Partners

Director · since 27 avril 2023 · until 27 avril 2027 · 0673.852.565

Represented by Danny Gonnissen

Active
KBC SECURITIES

Director · since 01 janvier 2023 · until 24 juin 2025 · 0437.060.521

Represented by Jeroen Van den Bossche

Active
BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL

Director · since 30 juin 2022 · until 30 juin 2026 · 0475.471.036

Represented by Hugo Van Heuverswyn

Active
BIOQUBE VENTURES

Chairman of the board of directors · since 30 juin 2022 · until 30 juin 2026 · 0738.714.089

Represented by Dirk Reyn

Active
Biotalys

Director · since 30 juin 2022 · until 30 juin 2026 · 0508.931.185

Represented by Toon Musschoot

Active
Flen Health Pharma

Director · since 30 juin 2022 · until 30 juin 2026 · 0473.295.959

Represented by Philippe Sollie

Active
Interuniversitair Micro-Electronica Centrum

Director · since 30 juin 2022 · until 30 juin 2026 · 0425.260.668

Represented by Jo De Boeck

Active
IQVIA Solutions Belgium

Director · since 30 juin 2022 · until 30 juin 2026 · 0400.502.211

Represented by Michele Cimmino

Active
Lakefront Biotherapeutics

Director · since 30 juin 2022 · until 30 juin 2026 · 0466.460.429

Represented by Erik Present

Active
VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY

Director · since 30 juin 2022 · until 30 juin 2026 · 0456.343.923

Represented by Jérôme Van Biervliet

Active
BASF BELGIUM COORDINATION CENTER

Director · since 24 juin 2021 · until 24 juin 2025 · 0862.390.376

Represented by Erik van de Biezen

Active
Janssen Pharmaceutica

Director · since 24 juin 2021 · until 24 juin 2025 · 0403.834.160

Represented by Tom Aelbrecht

Active
ViroVet

Director · since 24 juin 2021 · until 24 juin 2025 · 0634.891.328

Represented by Erwin Blomsma

Active
ETHERNA IMMUNOTHERAPIES

Director · since 23 juin 2020 · until 20 juin 2024 · 0502.703.389

Represented by Bernard Sagaert

Active

Ended mandates

BIOQUBE VENTURES

Director · since 30 juin 2022 · until 30 juin 2026 · 0738.714.089

Represented by Dirk Reyn

Ended
BASF BELGIUM COORDINATION CENTER

Director · since 24 juin 2021 · until 24 juin 2025 · 0862.390.376

Represented by Erik van der Biezen

Ended
KBC SECURITIES

Director · since 24 juin 2021 · until 24 juin 2025 · 0437.060.521

Represented by Nathalie Van Den Haute

Ended
2 BRIDGE

Director · since 23 juin 2020 · until 22 juin 2024 · 0540.765.892

Represented by Ann Meulemans

Ended
Annual accounts

Full financial information

202420232022202120202019
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202401/01/202301/01/202201/01/202101/01/202001/01/2019
Closing of the financial year31/12/202431/12/202331/12/202231/12/202131/12/202031/12/2019
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date10/06/202518/07/202425/05/202312/07/202208/07/202116/07/2020
General meeting27/05/202520/06/202427/04/202330/06/202224/06/202123/06/2020
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

19 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202427/05/202510/06/2025DutchPDF
Abridged model31/12/202320/06/202418/07/2024DutchPDF
Abridged model31/12/202227/04/202325/05/2023DutchPDF
Abridged model31/12/202130/06/202212/07/2022DutchPDF
Abridged model31/12/202024/06/202108/07/2021DutchPDF
Abridged model31/12/201923/06/202016/07/2020DutchPDF
Abridged model31/12/201828/03/201926/04/2019DutchPDF
Abridged model31/12/201721/06/201811/07/2018DutchPDF
Abridged model31/12/201620/04/201706/06/2017DutchPDF
Abridged model31/12/201521/04/201609/05/2016DutchPDF
Abridged model31/12/201426/06/201509/09/2015DutchPDF
Abridged model31/12/201326/05/201418/06/2014DutchPDF
Abridged model31/12/201213/06/201320/06/2013DutchPDF
Abridged model31/12/201118/04/201210/05/2012DutchPDF
Abridged model31/12/201007/04/201104/07/2011DutchPDF
Abridged model31/12/200922/04/201019/05/2010DutchPDF
Abridged model31/12/200823/04/200918/06/2009DutchPDF
Abridged model31/12/200707/03/200809/05/2008DutchPDF
Abridged model31/12/200616/03/200725/02/2008DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 18 active · 159 ended

Active mandates

2 BRIDGE

Director · since 20 juin 2024 · until 20 juin 2028 · 0540.765.892

Represented by Ann Meulemans

Active
Participatiemaatschappij Vlaanderen

Director · since 20 juin 2024 · until 20 juin 2028 · 0455.777.660

Represented by Kenneth Wils

Active
QbD Group

Director · since 20 juin 2024 · until 20 juin 2028 · 0838.540.254

Represented by Bart Van Acker

Active
Aphea.Bio

Director · since 27 avril 2023 · until 27 avril 2027 · 0666.961.607

Represented by Isabel Vercauteren

Active
Newton Biocapital Partners

Director · since 27 avril 2023 · until 27 avril 2027 · 0673.852.565

Represented by Danny Gonnissen

Active
KBC SECURITIES

Director · since 01 janvier 2023 · until 24 juin 2025 · 0437.060.521

Represented by Jeroen Van den Bossche

Active
BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL

Director · since 30 juin 2022 · until 30 juin 2026 · 0475.471.036

Represented by Hugo Van Heuverswyn

Active
BIOQUBE VENTURES

Chairman of the board of directors · since 30 juin 2022 · until 30 juin 2026 · 0738.714.089

Represented by Dirk Reyn

Active
Biotalys

Director · since 30 juin 2022 · until 30 juin 2026 · 0508.931.185

Represented by Toon Musschoot

Active
Flen Health Pharma

Director · since 30 juin 2022 · until 30 juin 2026 · 0473.295.959

Represented by Philippe Sollie

Active
Interuniversitair Micro-Electronica Centrum

Director · since 30 juin 2022 · until 30 juin 2026 · 0425.260.668

Represented by Jo De Boeck

Active
IQVIA Solutions Belgium

Director · since 30 juin 2022 · until 30 juin 2026 · 0400.502.211

Represented by Michele Cimmino

Active
Lakefront Biotherapeutics

Director · since 30 juin 2022 · until 30 juin 2026 · 0466.460.429

Represented by Erik Present

Active
VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY

Director · since 30 juin 2022 · until 30 juin 2026 · 0456.343.923

Represented by Jérôme Van Biervliet

Active
BASF BELGIUM COORDINATION CENTER

Director · since 24 juin 2021 · until 24 juin 2025 · 0862.390.376

Represented by Erik van de Biezen

Active
Janssen Pharmaceutica

Director · since 24 juin 2021 · until 24 juin 2025 · 0403.834.160

Represented by Tom Aelbrecht

Active
ViroVet

Director · since 24 juin 2021 · until 24 juin 2025 · 0634.891.328

Represented by Erwin Blomsma

Active
ETHERNA IMMUNOTHERAPIES

Director · since 23 juin 2020 · until 20 juin 2024 · 0502.703.389

Represented by Bernard Sagaert

Active

Ended mandates

BIOQUBE VENTURES

Director · since 30 juin 2022 · until 30 juin 2026 · 0738.714.089

Represented by Dirk Reyn

Ended
BASF BELGIUM COORDINATION CENTER

Director · since 24 juin 2021 · until 24 juin 2025 · 0862.390.376

Represented by Erik van der Biezen

Ended
KBC SECURITIES

Director · since 24 juin 2021 · until 24 juin 2025 · 0437.060.521

Represented by Nathalie Van Den Haute

Ended
2 BRIDGE

Director · since 23 juin 2020 · until 22 juin 2024 · 0540.765.892

Represented by Ann Meulemans

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2024
    Annual accounts 2024-355,7 k €
  2. 2023
    Annual accounts 202313,1 k €
  3. 2022
    Annual accounts 2022-108,9 k €
  4. 2022
    Name changeflanders.bio
  5. 2021
    Annual accounts 2021323,5 k €
  6. 2021
    Name changeFLANDERSBIO
  7. 2020
    Annual accounts 2020322,1 k €
  8. 2019
    Annual accounts 2019261,4 k €
  9. 2018
    Annual accounts 201814,5 k €
  10. 2017
    Annual accounts 2017-145,2 k €
  11. 2016
    Annual accounts 2016-26,6 k €
  12. 2015
    Annual accounts 2015-38,5 k €
  13. 2014
    Annual accounts 201424,8 k €
  14. 2013
    Annual accounts 2013137,4 k €
  15. 2012
    Annual accounts 20128,3 k €
  16. 2011
    Annual accounts 201126,2 k €
  17. 2010
    Annual accounts 201085,8 k €
  18. 2009
    Annual accounts 2009-22,3 k €
  19. 2008
    Annual accounts 2008-26,5 k €